Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research.
Andreas KerschbaumerJosef S SmolenPeter NashThomas DörnerMaxime DougadosRoy M FleischmannKlaus GeisslerIain B McInnesTsutomu TakeuchiMichael TraunerKevin WinthropMaarten P T de WitWolf-Henning BoehnckeLouise FalzonDésirée Mfm van der HeijdePublished in: RMD open (2021)
JAKi provide good efficacy compared to placebo (and to TNFi in RA and Pso) across various IMIDs with an acceptable safety profile. This SLR informed the task force on points to consider for the treatment of IMIDs with JAKi with the available evidence.